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Tracking the origin of simultaneous
endometrial and ovarian cancer by next-
generation sequencing – a case report
Nadejda Valtcheva1†, Franziska M. Lang2†, Aurelia Noske1, Eleftherios P. Samartzis2, Anna-Maria Schmidt2,
Elisa Bellini1, Daniel Fink2, Holger Moch1, Markus Rechsteiner1, Konstantin J. Dedes2* and Peter J. Wild1*
Abstract
Background: Endometrioid adenocarcinoma of the uterus and ovarian endometrioid carcinoma share many
morphological and molecular features. Differentiation between simultaneous primary carcinomas and ovarian
metastases of an endometrial cancer may be very challenging but is essential for prognostic and therapeutic
considerations.
Case Presentation: In the present case study of a 33 year-old patient we used targeted amplicon next-generation
re-sequencing for clarifying the origin of synchronous endometrioid cancer of the corpus uteri and the left ovary.
The patient developed a metachronous lung metastasis of an endometrioid adenocarcinoma four years after
hyster- and adnexectomy, vaginal brachytherapy and treatment with the synthetic steroid tibolone. Removal of the
metastasis and megestrol treatment for seven years led to a complete remission.
A total of 409 genes from the Ampliseq Comprehensive Cancer Panel (Ion Torrent, Thermo Fisher) were analysed
by next generation sequencing and mutations in 10 genes, including ARID1A, CTNNB1, PIK3CA and PTEN were
identified and confirmed by Sanger sequencing. Primary endometrial as well as ovarian cancer showed an identical
mutational profile, suggesting the presence of an ovarian metastasis of the endometrial cancer, rather than a
simultaneous endometrial and ovarian cancer. The metachronous lung metastasis showed a different mutational
profile compared to the primary cancer. Immunohistochemical staining of the corresponding proteins suggested
that the tumour development was driven by alterations in the protein function rather than by changes of the
protein abundance in the cell.
Conclusions: Our results have demonstrated next generation sequencing as a valuable tool in the differentiation of
synchronous primary tumours and metastases, which has an important impact on the clinical decision making
process. Similar to breast cancer, targeted therapies based on mutational tumour profiling will become increasingly
important in endometrial and ovarian cancer. In summary, our results support the usage of next generation
sequencing as a supplementary diagnostic tool, assisting in personalized precision medicine.
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Background
Endometrioid adenocarcinoma of the uterus and ovarian
endometrioid carcinoma share many morphological and
molecular features [1, 2]. Coincidence of both primary
tumours is a relatively common event which occurs in
about 10% of patients with ovarian carcinoma and in about
5% with endometrial carcinoma [3]. When simultaneous
uterine and ovarian carcinomas show the same histology
and differentiation, determination of the primary origin
may be difficult. In case of independent primary tumours,
this might be due to the several common risk factors shared
by the two malignancies or due to germline alterations that
predispose to the development of simultaneous cancers. In
most cases, however, one of the endometrioid type carcin-
omas is the primary tumour that gives rise to a metastatic
lesion. It is also not excluded that both carcinomas might
originate from a common endometrial epithelial precursor
cell of origin, a theory that can explain the histological and
genetic similarities of the lesions [4]. Distinguishing be-
tween two independent lesions versus one primary and one
metastatic lesion is extremely difficult, nevertheless import-
ant for the prognosis and treatment of the patient [5].
A novel powerful tool to identify common genetic
alterations specific for a cancer entity and to provide
information on the tumour clonal evolution is next-
generation sequencing (NGS) [6]. To date, the know-
ledge of the mutational landscape of many different
tumours including endometrial and ovarian cancer has
increased throughout the last 10 years. TCGA has pub-
lished data from whole exome sequencing of a large
number of both gynaecological malignancies [1, 2].
Furthermore, studies have been reported on endometrial
and ovarian carcinoma using two different cohorts –
one including patients with endometrial endometrioid
carcinomas and one consisting of ovarian endometrioid
carcinomas [4]. The authors suggest that although the
same genes are affected in both cancers the mutation
patterns differ possibly due to the different microenvir-
onment in the ovary and the uterus. This offers a possi-
bility to determine the origin of simultaneously
identified endometrial and ovarian endometrioid lesions.
While these reports contribute to the big picture of what
are the most common aberrations in the corresponding
tumour type and beyond doubt profit from the large
number of cases investigated, single patients with syn-
chronously diagnosed endometrial and ovarian cancer
can shed light on the direct tumour evolution. Although
NGS is broadly used in preclinical research, thus provid-
ing the possibility to unravel genetic alterations and po-
tential therapeutic targets, in the clinical setting current
diagnostics and treatment of metastatic endometrial and
ovarian cancer is still mainly based on radiological and
conventional histological results as well as chemotherapy
combination regimens.
In the present case report we investigated the muta-
tion pattern in a 33-year-old female patient diagnosed
with synchronous endometrioid adenocarcinoma of the
corpus uteri and the left ovary. The patient developed a
lung metastasis of an endometrioid type adenocarcin-
oma four years after laparoscopic hysterectomy, vaginal
brachytherapy and tibolon therapy. Based on histological
findings, it is difficult to decide whether the gynaeco-
logical carcinomas are two independent primary carcin-
omas occurring in parallel. Furthermore, it is almost
impossible to recognize the origin of the lung mass.
Thus, we employed targeted NGS of 409 tumour-related
genes (Ion Ampliseq Comprehensive Cancer Panel,
Thermo Fisher) in order to identify the relation between
the two carcinomas and the source of the distant metas-
tasis. Moreover, we were interested in the genetic finger-
print of the metastasis to clarify the recurrence-free
survival of the patient after its removal and megestrol
treatment for seven years. Finally, we looked for possible
germline mutations from blood samples of the patient
that could explain the early onset of the disease.
Methods
Clinical history and pathological findings
A 33-year-old woman, who has undergone a diagnostic
curettage due to hypermenorrhoea and menorrhagia,
was diagnosed with endometrial endometrioid adenocar-
cinoma of moderate differentiation and with squamous
components. Subsequently, a laparoscopic hysterectomy
with pelvic washing, bilateral adnexectomy and pelvic
lymphadenectomy was performed. In the hysterectomy,
well-differentiated residual cancer was found with infil-
tration less than one half of the myometrium, consistent
with stage pT1a.
The tumour tissue showed high expression of
oestrogen and progesterone receptors (both 100%, Fig. 3).
Unexpectedly, a synchronous well differentiated endo-
metrioid adenocarcinoma with squamous components
of the left ovary was detected. The tumour mass was
confined to the ovary according to stage pT1a. The
contralateral ovary showed no pathological alterations.
All pelvic lymph nodes (n = 20) were free of tumour. In
summary, the former pathological TNM classification
for the corpus uteri was pT1a pN0 (0/20) G2 (FIGO
stage IA) and for the ovary pT1a pN0 G1 (FIGO stage
IA). Vaginal brachytherapy of 4x5 Gy was administered
because of a G2 tumour and the quite young age of the
patient. After treatment with tibolon (2.5 mg/day) for
4 years, the patient presented with chest pain in the
right upper thorax. Through CT-scan and the following
thoracoscopic resection of the right upper lobe of the
lung, a metastatic endometrioid adenocarcinoma was
removed. Treatment with megestrol (160 mg/day) was
started. In addition to the clinical check-up, a CT-scan
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was performed each year. The latest PET–CT scan after
7 years being treated with megestrol acetate showed no
evidence of tumour recurrence. Informed consent was
obtained and the study has been approved by the local
ethics committee (KEK-ZH-No. 2010–0358).
Immunohistochemical analysis
Tumour tissue sections were immunohistochemically
investigated with the following antibodies: oestrogen
receptor (SP1 Ventana-Roche, prediluted), progesterone
receptor (1E2, Ventana-Roche, prediluted), mismatch
repair proteins as MSH2 (25D12, Novocastra Lab Ltd.,
1:100), MSH6 (BD Biosciences 1:500), MLH1 (G168-15,
PharMingen Becton Dickinson 1:100), PMS2 PharMingen
BD 1:300), PTEN (6H2.1 DAKO, 1:200), beta-Catenin (14/
beta-Catenin, BD Biosciences, 1:50), ARID1A/BAF250a
(HPA005456, Sigma Chemicals, 1:200), and γH2AX (Novus
Biologicals, 1:1200).
After antigen retrieval, the slides were incubated with
the primary antibodies. After incubation for 1 h at
room temperature, the staining of ER, PR, beta-Ca-
tenin, and γH2AX was further conducted with the
Ventana Benchmark automated system (Ventana Medical
Systems, USA) using Ventana reagents such as UltraView
HRP (for ER, PR), UltraMap™ DAB detection kit for
γH2AX, and Optiview (beta-Catenin). The antibodies
against the mismatch repair proteins and ARID1A
were incubated for 30 min and the staining procedure
was carried out with the automated Leica BOND
system using the Bond Polymer Refine Detection Kit
(Leica Biosystems).
DNA extraction
Histological slides from FFPE tissue specimens were
reviewed for tumour content and the tumour area was
marked by a trained gynaecopathologist for tissue
punching (Fig. 2). DNA from peripheral blood and FFPE
punches (3 cylinders with diameter of 0.6 mm) was
isolated with the Maxwell 16 LEV Blood DNA kit (Pro-
mega, #AS1290) and Maxwell 16 FFPE Tissue LEV
DNA Purification Kit (Promega, #AS1130), respectively,
according to the manufacturer’s recommendations.
Briefly, 300 μl of blood collected in a BD Vacutainer K2
(EDTA 18.0 mg) tube was added to 30 μl of Proteinase
K solution (final concentration 2 mg/ml) and subse-
quently mixed with 300 μl lysis buffer, vortexed and
incubated for 20 min at 56 °C. FFPE cylinders were
deparaffinised with xylene, washed twice with ethanol,
dried 10 min at 37 °C and resuspended in 200 μl incuba-
tion buffer containing 2 mg/ml Proteinase K. Samples
were incubated overnight at 70 °C and mixed with
400 μl lysis buffer. Lysates from both, blood and FFPE
tissue were transferred to well 1 of the supplied cartridge
of the corresponding kit and DNA was automatically
purified and eluted in 30 μl Tris-buffer, pH 8.0 by the
Maxwell instrument.
Next generation sequencing (NGS)
Targeted NGS of 409 cancer related genes was per-
formed with 40 ng DNA using the Ion AmpliSeq Com-
prehensive Cancer Panel (Thermo Fisher Scientific)
according to the manufacturer’s protocol. Alignment,
variant calling and filtering were performed with Ion
Reporter 4.4 (Thermo Fisher Scientific). The following
filter chain was used: “Location in utr_3, splicesite_3,
exonic, splicesite_5, utr_5” in, “variant effect in stoploss,
nonsense, missense, frameshiftInsertion notframeshiftIn
sertion, nonframeshiftBlockSubstitution, frameshiftDe
letion, nonframeshiftDeletion, frameshiftBlockSubstitu
tion” in, “USCS Common SNPs” not in, allele ratio
between 0.05 and 1.0 in, allele read-count between 100
and 100 000 in, variant type “INDEL, LONGDEL, SNV,
MNV” in. Variants selected after visual inspection of
the reads in IGV that displayed more than 15% vari-
ant frequency were verified with Sanger sequencing
(Additional file 1: Table S1).
Sanger sequencing
Primers were designed to amplify 200 bp fragments
surrounding the position of the detected variant
(Additional file 1: Table S1). PCR products were purified
and subjected to Sanger sequencing in two reactions,
one with the forward and one with the reverse primer.
Results
Histopathological considerations
Histopathological evaluation of the simultaneous endo-
metrial and (unilateral) ovarian cancer as well as the
lung metastasis revealed the same tumour morphology,
showing an endometrioid adenocarcinoma with low
grade features and squamous components (Fig. 1). Squa-
mous differentiation is a common feature of endome-
trioid type cancer and may occur in both endometrial
and ovarian tumours. Precursor lesions like endometrial
hyperplasia or components of an ovarian borderline-
tumour or endometriosis were not identified.
In summary, the endometrial and ovarian neoplasms
showed the very same histomorphology and differenti-
ation, and no precursor lesions were found, neither in
the ovary, nor in the uterus. The primary site of cancer
origin, however, could not be clarified with this observa-
tion. To further address this key question we first com-
pared the size of the lesions. Since the endometrial
carcinoma was larger than the ovarian tumour, the
uterus is in favour of the primary origin. However, a
common or multifocal origin can also be hypothesized.
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Genetic alterations (NGS)
To gain insight into the tumour biology we used tar-
geted deep re-sequencing. DNA was extracted from the
tumour area and the correct excision of the FFPE
punches was confirmed with HE staining (Additional file
2: Figure S1). 409 genes were re-sequenced with the Ion
AmpliSeq Comprehensive Cancer Panel (Thermo Fisher
Scientific). Variants present in the blood were excluded
(the full table of variants from two technical replicates
are listed in Additional file 1: Table S2) and the variants
of interest with a frequency of more than 15% were veri-
fied with Sanger sequencing (Additional file 2: Figure S2
and data not shown). The variant frequency in each
sample was determined as percent variant reads from
total reads.
Somatic mutations in ARID1A, RAF1, CTNNB1,
PIK3CA, ESR1, SYNE1, PIK3CG PTEN, PTPRT and USP9X
were detected (Table 1, Fig. 2a). PhyloP, SIFT, Grantham,
PolyPhen are different algorithms predicting the damage
caused by a mutation and at least one of them suggested
impaired protein function arising from all listed mutations.
Furthermore, the SNVs in CTNNB1, PIK3CA, PTEN and
ESR1 were annotated in COSMIC, the catalogue of somatic
mutations in cancer.
Interestingly, SNVs in PTEN (p.Cys124Ser and
p.Ala126Thr) and PTPRT (p.Val1429Met), and one-base
indels in RAF1 (p.Met350fs) and ARID1A (p.Arg1053fs)
were shared by the endometrial and ovarian carcinomas
but not found in the lung metastasis. On the other
hand, the lung metastasis carried mutations in ESR1
(p.Tyr537Cys) and PTEN (p.Asp92Tyr) that were not
detected in the endometrial and ovarian carcinomas.
USP9X (p.Met1478Leu) was mutated only in the ovarian
adenocarcinoma. In contrast, PIK3CG (p.Ser931Cys) was
altered only in the endometrial adenocarcinoma.
The general distribution of the detected mutations
showed that most of them (8/12) are shared by the
endometrial and ovarian tumour. Only a single private
mutation in the ovarian and endometrial lesion was
found (Fig. 2b). Three of eight mutations were also
detected in the lung metastasis, although with lower
frequencies (Fig. 2a and b). Further, the lung metastasis
had acquired two additional mutations.
Protein expression profile (immunohistochemistry)
The immunohistochemical profile was consistent in all
three cancer manifestations. The hormone receptor
expression was strong in almost 100% of tumour nuclei.
The expression of four mismatch repair proteins (MSH2,
MLH1, MSH6, PMS2) was visible in normal and tumour
tissue, suggestive of microsatellite stable (MSS) carcinomas
(Fig. 3). Expression of PTEN, beta-Catenin, and ARID1A
was observed in all tumour samples (Fig. 4). γH2AX stain-
ing was used as a surrogate marker for double strand
breaks. Nuclear γH2AX expression was observed in single
cells of the ovarian tumour but less in the endometrial and
metastatic tumour. Interestingly, the expression was found
not only in the glandular tumour component but also in
the squamous part (data not shown).
Fig. 1 Tumour samples used in the study and representative images of the simultaneous endometrial and ovarian carcinoma as well as the lung
metastasis. a Endometrioid adenocarcinoma with focal squamous component. b Endometrioid adenocarcinoma involving the ovary. On the right
upper side an ovarian follicle is present. c Endometrioid carcinoma with infiltration of lung tissue. Hematoxylin and eosin staining; original
magnification 20x
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Discussion
In the present study, we investigated the molecular
profile of a simultaneous low-grade endometrioid endo-
metrial and ovarian carcinoma as well as of a lung me-
tastasis in a young female patient. From the histology
alone, the primary origin is sometimes difficult to deter-
mine. The identification of precursor lesions, the pattern
of spread and tumour size are valuable parameters for
this differentiation. Immunohistochemical analysis of
hormone receptors, PTEN and beta-Catenin may show
overlapping staining patterns and is therefore not always
helpful. The simultaneous occurrence of an endometrial
and ovarian carcinoma in women below 50 years of age
is a common combination [3], however, the pattern of
pulmonary metastasis in this low grade and low stage
cancer disease is unusual.
In our molecular analysis, we detected and verified
mutations in genes such as ARID1A, CTNNB1, PIK3CA,
and PTEN which are frequently affected in these tumour
entities [7, 8]. However, no striking alterations in
mismatch repair genes known to cause early develop-
ment of endometrial cancer were detected.
We further showed that some mutations were lost
during the metastasis formation, either due to the treat-
ment or because of redundancy with other alterations
affecting the same pathway. Last but not least, we identi-
fied enrichment of mutations causing upregulation of
PI3K signalling that could explain the prolonged
complete remission under megestrol acetate.
Somatic mutations were identified with targeted PCR-
based NGS and verified with Sanger sequencing. The fact
that 67% (8/12) of the detected alterations were shared by
the ovarian and endometrial tumour with similar variant
frequencies suggests a common origin of the two lesions.
PTEN is more frequently mutated in low-grade endomet-
rial endometrioid carcinomas (67%) compared to low-
grade ovarian endometrioid carcinomas (17%). In con-
trast, CTNNB1 mutations are significantly different in
low-grade ovarian endometrioid carcinomas (53%) com-
pared to 28% of the low-grade endometrial endometrioid
Fig. 2 Mutational landscape of the endometrial and ovarian adenocarcinomas and the lung metastasis. a Overview of the mutated genes and
the positions of the mutations detected with targeted NGS. The intensity of the blue colour encodes for the frequency of the corresponding
mutation in each sample (see scale). b Venn diagram representation of the number of mutations in each specimen and their overlap. EmCa,
endometrial carcinoma; OvCa, ovarian carcinoma; Meta, lung metastasis
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Fig. 3 Oestrogen receptors (ER; b, g, l), progesterone receptors (PR; c,h,m) and mismatch repair protein (examples for MSH2 and MLH1; d, i, n
and e, j, o) immunohistochemical staining of the endometrial carcinoma (EmCa, a-e), the ovarian carcinoma (OvCa, f-j), and of the lung
metastasis (Meta, k-o). Hematoxylin and eosion staining is also shown (a, f, k); original magnification 20x
Fig. 4 PTEN (a, e, i), ARID1A (b, f, j), CTNNB1 (c, g, k) and P-4E-BP1 (d, h, l) immunohistochemical staining of endometrial carcinoma (EmCa, a-d),
ovarian carcinoma (OvCa, e-h), and of the lung metastasis (Meta, i-l); original magnification 20x
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carcinomas [4]. In the present case, both genes were mu-
tated in both tumours, hampering the unambiguous iden-
tification of the primary lesion. However, all shared
mutations showed a slightly higher variant frequency in
the endometrial adenocarcinoma. Based on this observa-
tion it is tempting to speculate that the endometrial
adenocarcinoma gave rise to the ovarian adenocarcinoma.
The clones that populated the ovary seemed to be of
mixed origin and the cells containing the mentioned mu-
tations could have lost their selection advantage in the
ovarian microenvironment. The origin of the lung metas-
tasis, however, could not be specified unambiguously.
The early onset of the malignant disease in this young
woman at age 33 suggests possible germline mutations
that accelerated the accumulation of genetic aberrations
promoting cancer development. A common genetic
defect that leads to the development of endometrial
cancer in the context of Lynch syndrome is aberrations
in the mismatch repair (MMR) proteins. Interestingly,
neither mutations in the MMR genes nor increased
double strand breaks could be detected. Another pos-
sible cause of the early disease onset is Cowden’s syn-
drome. Targeted PCR-based re-sequencing, however,
is not the ideal method to detect large gene deletions.
The uniformity blot (sequencing depth across ampli-
cons) for the PTEN gene showed no inconsistencies.
Therefore, larger deletions on chromosome 10 were
unlikely. In addition, germline PTEN mutations could
be ruled out.
The one base insertion detected in gene ARID1A
causes a frame shift at codon 1053 of the protein. Since
the percentage of the mutation suggested a heterozygous
alteration, the sustained immunohistochemical staining
is probably due to wild-type ARID1A expressed in the
tumour samples. However, our study does not provide
information on the expression status of the mutated pro-
tein or possible dominant negative interference with
wild-type ARID1A. The mutation was not present in the
metastasis or present at a low percentage from a mar-
ginal subclone indicating that this mutation was not
substantially contributing to the tumour spread.
In contrast, the somatic mutations in CTNNB1 and
PIK3CA were detected not only in the endometrial and
ovarian tumours, but also in the lung metastasis. Both
mutations are reported in COSMIC, providing experimen-
tal evidence that both mutations affect the function of the
each protein and are pathogenic. The amino acid change
p.Thr41Ile caused by the SNV c.122C > T in CTNNB1 in-
creases protein stability of beta-catenin and leads to its
relocalisation to the nucleus [9]. The SNV c.1637A >G in
PIK3CA results in a mutant PI3K displaying increased
substrate phosphorylation [10]. Hyperactivation of the
PI3K pathway is a known cancer driving event in endo-
metrial cancer [8].
Another key protein that is a part of the same signalling
cascade and was affected by gene mutations in the de-
scribed case is the tumour suppressor PTEN. The PTEN
SNV c.370 T >A results in replacement of the cysteine in
the active site against serine (p.C124S) leading to an enzy-
matically inactive protein. Although, as shown by immu-
nohistochemistry, the protein level was not affected and
the mutation was likely to be heterozygous, it has been re-
cently reported that this enzymatically dead mutant in-
hibits wild-type PTEN in a dominant negative manner
[11]. Additionally, we found a second PTEN mutation
(c.376G > A) that leads to a threonine replacing the ala-
nine at the adjacent position 126 of the protein, likely to
distort the tertiary structure of the active site. None of the
PTEN mutations could be detected in the lung metastasis.
Instead, another PTEN mutation (p.Asp92Tyr) was de-
tected in the lung metastasis that is also annotated in
COSMIC. A possible explanation for the loss of the dom-
inant negative PTEN mutation is the biological redun-
dancy of the PTEN inactivating and PIK3CA activating
mutations that both lead to an elevated signalling through
the PI3K pathway. Indeed, there is evidence that single
clones from the primary tumour are able to colonise dis-
tant organs and that the metastases carry rather less muta-
tions than the primary tumour due to natural selection
process that sustains only the aberrations indispensable
for tumour cell survival and proliferation [12]. Interest-
ingly, four years after surgery the patient presented with a
lung metastasis that was excised and a therapy with
megestrol acetate was initialised. To date, the patient is
recurrence-free. Megestrol acetate is reported to act
through de-phosphorylation of the PI3K downstream tar-
get Akt [13], which might be a possible reason for the
complete response of the patient to the treatment.
It has been shown very recently by two independent
groups that a majority of synchronous endometrial and
ovarian endometrioid carcinomas show clear evidence of
clonality [14, 15]. The findings of these two studies
strongly indicate that a considerable part of clinically
synchronous endometrial and ovarian endometrioid
carcinomas constitute in fact dissemination from one
site to the other which is also very likely in our case. In
our study we extend these results by next generation
sequencing analysis of a distant metastasis and demon-
strated that not all mutations found in the primary
tumour were conserved in the metastasis. This is illus-
trated e.g. by the SNVs in PTEN (p.Cys124Ser and
p.Ala126Thr) and ARID1A (p.Arg1053fs) which were
found in both, the endometrial and the ovarian endome-
trioid carcinoma, but were not conserved in the distant
lung metastasis. Co-occurrence of mutations in ARID1A
and PTEN have been shown as potential cancer driving
mutations in endometrioid ovarian carcinomas in animal
models [16]. Interestingly, these two mutations were not
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conserved in the distant metastasis, indicating another
clonal event. Neither the PTEN nor the ARID1A mutation
has given rise to the distant metastasis. To our knowledge
this is the first case demonstrating the lack of an ARID1A
mutation in a distant metastasis of an ARID1A mutated
primary tumour. This demonstrates that even very frequent
and potential cancer driving mutations such as PTEN and
ARID1A in endometrioid endometrial and ovarian cancer
may not be found in distant metastases, a fact that is essen-
tial for potential future targeted therapies [17–19]. How-
ever, this also demonstrates the importance of sequencing
metachronous distant metastases since its mutational
profile may differ from the profile of the primary tumour.
Conclusions
In conclusion, our results demonstrate that next gener-
ation sequencing is an important tool in the differenti-
ation of simultaneous primary tumours and metastases,
which has an important impact for clinical practice. This
may not only be valuable information for prognostic
considerations, but also may be of increasing importance
for future targeted therapies.
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